Fatal Outcome in Comorbidity Aggravated by Hypoglycemia

L.V. Shkala, H.I. Myshanych, Ye.V. Babakova

Abstract


The paper presents a fatal case after severe hypoglycemia in 45-year-old patient with comorbidity. The combination of coronary heart disease, cardiosclerosis with atrial fibrillation, complicated by heart failure III stage, and severe type 2 diabetes mellitus at the stage of decompensation, on the background of stage III essential hypertension and stage III obesity has a very poor prognosis. The presence of severe metabolic, hormonal and functional disorders leads to a complete depletion of the compensatory capacity of the body. Under prolonged hypoglycemia in combination with disorders of the central regulatory systems, processes of microcirculation, clinical death was inevitable despite intensive care.


Keywords


comorbidity; coronary artery disease; heart failure; type 2 diabetes mellitus; hypoglycemia

References


Воропай Т.И. Дифференциальная диагностика гипогликемии различного генеза // Матер. 51-ї наук.-практ. конф. «Ендокринологічна допомога населенню України: нові діагностичні можливості та лікувальні технології». — Харків, 2007. — С. 23-33.

Демидова Т.Ю. Атеросклероз и сахарный диабет 2: механизмы и управление // Кардиосоматика. — 2011. — Т. 2, № 2. — С. 22-30.

Запрянова Д.С., Мирчева Т.Г., Динев Т.Г. Влияние некоторых антикоагулянтов на динамику концентрации сахара в крови коз // Вісник Дніпропетровського університету. Біологія, екологія. — 2007. — Т. 1, вип. 15.

Mandric O., Severens J.L., Pan’kiv V.I. et al. Impact of hypoglycemia on daily life of type 2 diabetes patients in Ukraine // Journal of Multidisciplinary Healthcare. — 2013. — Vol. 2013, № 6. — P. 249-257. https://www.dovepress.com/submit_step_1.phphttps://www.dovepress.com/login.php.

Корчина Т.Я. Ишемическая болезнь сердца при сахарном диабете. Вопросы патогенеза, диагностики и хирургического лечения. — Томск: STT, 2002. — 352 с.

Лупанов В.П. Безболевая ишемия миокарда: диагностика, медикаментозное и хирургическое лечение, прогноз (обзор литературы) // Consilium Medicum (кардиология). — 2012. — Т. 14, № 10. — С. 36-44.

Маньковский Б.Н. Терапия сахарного диабета 2-го типа: нереализованные потребности и новые возможности // Діабет. Ожиріння. Метаболічний синдром. — 2014. — № 4(ІІІ). — С. 37-41.

Панькив В.И. Клинически значимые различия между препаратами сульфонилмочевины: шаг вперед в профилактике сердечно-сосудистых осложнений у пациентов с СД 2-го типа // Міжнародний ендокринологічний журнал. — 2006. — № 4(6). — С. 49-55.

Терещенко С.Н., Джаиани Н.А., Голубев А.В. Ишемическая болезнь сердца и сахарный диабет // Consilium Medicum. — 2005. — № 5. — Р. 364-368.

Bayturan O., Tuzcu E.M., Uno K. et al. Comparison of rates of progression of coronary atherosclerosis in patients with diabetes mellitus versus those with the metabolic syndrome // Am. J. Cardiol. — 2010. — Vol. 105, № 12. — P. 1735-1739.

Buse J.B., Ginsberg H.N., Bakris G.L. et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association // Circulation. — 2007. — Vol. 115. — P. 114-126.

Colhoun H.M., Betteridge D.J., Durrington P.N. et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomized placebo-controlled trial // Lancet. — 2004. — Vol. 364. — P. 685-696.

Donnelly L.A., Morris A.D., Frier B.M. Frequency and predictors of hypoglycaemia in Type 1 and insulin treated Type 2 diabetes: a population-based study // Diabet. Med. — 2005. — Vol. 22. — P. 749-755.

Fihn S.D., Cardin J.M., Abrams J. et al. ACCF/AHA/ACP/FCP/AATS/PCNA/SCAI/SNS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease // J. Am. Coll. Cardiol. — 2012. — Vol. 60, № 24. — P. 44-164.

Heart Protection Study Collaboration Group. MRC/BHF Heart Protection Study of choresterol lowering in 5963 people with diabetes: a randomized placebo-controlled trial // Lancet. — 2003. — Vol. 361. — P. 205-216.

Hlatky M.A., Boothroyd D.B., Bravata D.M. et al. Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: a collaborative analysis of individual patient data from ten randomised trials // Lancet. — 2009. — Vol. 373. — P. 1190-1197.

Kolh P., Wijns W., Danchin N. et al. Guidelines on myocardial revascularization. Task Force on myocardial revascularization of the European Society Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS); European Association for Percutaneous Cardiovascular Intervention (EAPCI) // Eur. J. Cardiothorac. Surg. — 2010. — Vol. 38. — P. 1-52.

Nicholls S.J., Tuzcu E.M., Kalidindi S. et al. Effect of diabetes on progression of coronary atherosclerosis and arterial remodeling: a pooled analysis of 5 intravascular ultrasound trials // J. Am. Coll. Cardiol. — 2008. — Vol. 52, № 4. — Р. 255-262.

Rogin G., Unwit N., Bennett P.H. et al. The burden of mortality attributable to diabetes: realistic estimated for the year 2000 // Diabetes Care. — 2005. — Vol. 28. — P. 2130-2135.

Saleem T., Mohammad K.H., Abdel-Fattah M.M. et al. Association of glycosylated haemoglobin level and diabetes mellitus duration with the severity of coronary artery disease // Diab. Vasc. Dis. Res. — 2008. — Vol. 5. — P. 1849.




DOI: https://doi.org/10.22141/2224-0721.1.65.2015.75929

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© "Publishing House "Zaslavsky", 1997-2018

 

   Seo анализ сайта